Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma
Crossref DOI link: https://doi.org/10.1007/s11307-014-0764-x
Published Online: 2014-08-01
Published Print: 2015-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Baron Toaldo, Marco
Salvatore, Veronica
Marinelli, Sara
Palamà , Chiara
Milazzo, Maddalena
Croci, Luca
Venerandi, Laura
Cipone, Mario
Bolondi, Luigi
Piscaglia, Fabio
Text and Data Mining valid from 2014-08-01